Table 2.
DAS28 up to week 48 after the first course of CT-P10 or innovator ritixumab (safety populationa; baseline observation carried forwardb)
| Visit | CT-P10 (n = 102) | RTX (n = 51) |
|---|---|---|
| DAS28-ESR | ||
| Baseline | 6.80 ± 0.86 | 6.74 ± 0.85 |
| Week 24 | 4.86 ± 0.21 | 4.85 ± 0.25 |
| Week 48 | 6.37 ± 0.17 | 6.10 ± 0.20 |
| DAS28-CRP | ||
| Baseline | 6.01 ± 0.90 | 5.96 ± 0.88 |
| Week 24 | 4.12 ± 0.20 | 4.09 ± 0.24 |
| Week 48 | 5.61 ± 0.16 | 5.35 ± 0.19 |
Baseline values are mean ± SD; values at week 24 and 48 are adjusted mean ± SE
ANCOVA analysis of covariance, BOCF baseline observation carried forward, CRP C-reactive protein, DAS28 Disease Activity Score using 28 joints, ESR erythrocyte sedimentation rate, RTX innovator rituximab, SD standard deviation, SE standard error
aAll patients who received at least one (full or partial) dose of CT-P10 or RTX
bIn this ANCOVA analysis, missing data and data for visits after re-treatments were imputed using the conservative BOCF approach